David Reese retirement prompts organizational changes at Amgen.

{
  "signal_id": "15984688-2d45-47bf-8095-ac9ab65db4e1",
  "signal_type": "news",
  "signal_subtype": "retires_from",
  "detected_at": "2026-04-22T20:03:08+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "url": "https://www.thepharmaletter.com/biotech-news/david-reese-retirement-prompts-organizational-changes-at-amgen",
    "title": "David Reese retirement prompts organizational changes at Amgen.",
    "contact": "David Reese",
    "excerpt": "David Reese retirement prompts organizational changes at Amgen.\n\n23 April 2026\n\nUS biotech major Amgen (Nasdaq: AMGN) has announced the retirement of David Reese, executive vice president and chief technology officer, effective June 30.\n\nThis article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.\n\nTry before you buy\n\nFree.\n\n7 day trial access\n\n* All the news that moves the needle in pharma and biotech\n* Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters.\n* Receive The Pharma Letter daily news bulletin, free forever.\n\nBecome a subscriber\n\n£820.\n\nOr £77 per month\n\n* Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.\n* Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.\n* Daily roundup of key events in pharma and biotech.\n* Monthly in-depth briefings on Boardroom appointments and M&A news.\n* Choose from a cost-effective annual package or a...",
    "summary": "David Reese will retire from Amgen Foundation, Inc. as executive vice president and Chief Technology Officer on Jun 30th '26.",
    "category": "retires_from",
    "found_at": "2026-04-22T20:03:08Z",
    "planning": false,
    "image_url": "https://cdn.thepharmaletter.com/convert/files/2024/04/05ab5590-0154-11ef-a588-e798d47e404e-amgen_hq_large-1.jpg/r%5Bwidth%5D=1280/05ab5590-0154-11ef-a588-e798d47e404e-amgen_hq_large-1.jpg",
    "job_title": "executive vice president and Chief Technology Officer",
    "confidence": 0.4674,
    "assets_tags": [
      "research_and_development"
    ],
    "product_tags": [
      "general_technology"
    ],
    "published_at": "2026-04-23T00:00:00Z",
    "effective_date": "2026-06-30",
    "job_title_tags": [
      "general_technology",
      "directors",
      "engineering"
    ],
    "article_sentence": "US biotech major Amgen (Nasdaq: AMGN) has announced the retirement of David Reese, executive vice president and chief technology officer, effective June 30."
  }
}

curl https://signals.autobound.ai/v1/signals/15984688-2d45-47bf-8095-ac9ab65db4e1 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"amgen.com","limit":20}'